Christian Funke

USPTO Granted Patents = 53 (Patent Applications = 4)

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 32 (Patent Applications = 31)

Average Co-Inventor Count = 5.5

ph-index = 7

Forward Citations = 137(Granted Patents)

Forward Citations (Not Self Cited) = 121(Oct 12, 2025)

Inventors with similar research interests:

Company Filing History:

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

patents

where one patent can have more than one assignee

Years Active: 2007-2023

Loading Chart...

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11760737 - Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine (2023-09-19),

2. 10906893 - Method for preparing methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate (2021-02-02),

3. 10604495 - Process for preparing substituted phenylisoxazoline derivatives (2020-03-31),

4. 10435352 - Method for synthesizing 2-alkyl-4-trifluoromethyl-3-alkylsulfonylbenzoic acids (2019-10-08),

5. 10189800 - Method for preparing N-(1,3,4-oxadiazol-2-yl)arylcarboxamides (2019-01-29),

6. 10189799 - Process for preparing substituted phenylisoxazoline derivatives (2019-01-29),

7. 9968086 - Active ingredient combinations having insecticidal and acaricidal properties (2018-05-15),

8. 9957256 - Process for the preparation of 5-fluoro-1H-pyrazoles starting from hexafluoropropene (2018-05-01),

9. 9725415 - Process for the preparation of 5-fluoro-1H-pyrazoles (2017-08-08),

10. 9701640 - Process for preparing 3,5-bis(haloalkyl)pyrazole derivatives from α,α-dihaloamines and ketimines (2017-07-11),

11. 9700049 - Anthranilamides in combination with fungicides (2017-07-11),

12. 9630898 - Method for producing halogenketones (2017-04-25),

13. 9376389 - Process for preparing 2,2-difluoroethylamine derivatives by alkylating 2,2-difluoroethylamine (2016-06-28),

14. 9265255 - Anthranilamides in combination with fungicides (2016-02-23),

15. 9198424 - Active ingredient combinations having insecticidal and acaricidal properties (2015-12-01),

Title: Christian Funke: Innovator in Pharmaceutical Processes

Introduction

Christian Funke, a prolific inventor based in Leichlingen, Germany, has made significant contributions to the field of pharmaceuticals with 53 patents to his name. His innovations focus primarily on efficient processes that aid in the preparation of critical medicinal compounds, especially those related to cardiovascular treatment.

Latest Patents

Among his most recent innovations is a patent for a "Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine." This method presents a cost-effective and efficient means to prepare this compound, which serves as an essential intermediate in the production of medicaments aimed at treating and preventing cardiovascular disorders. Another noteworthy invention is his "Method for preparing methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate." This innovative method allows for the preparation of this compound using specific chemicals and conditions, highlighting Funke's ingenuity in advancing medicinal chemistry.

Career Highlights

Christian Funke has built a remarkable career, holding significant positions at Bayer CropScience AG and Bayer Intellectual Property GmbH. His work at these esteemed organizations has allowed him to refine his skills and develop numerous patents, solidifying his reputation as an expert in pharmaceutical innovation.

Collaborations

Throughout his career, Funke has collaborated with notable professionals, including Rüdiger Fischer and Heike Hungenberg. These partnerships have contributed to the success of his inventions and showcase the importance of collaboration in advancing technology and innovation within the pharmaceutical industry.

Conclusion

Christian Funke’s dedication to innovation is evident in his extensive portfolio of patents and his contributions to the field of pharmaceuticals. His breakthroughs in the preparation of critical compounds demonstrate his commitment to enhancing medical treatments and improving patient outcomes, cementing his legacy as an influential inventor in the industry.

This text is generated by artificial intelligence and may not be accurate.